CLINICAL TRIAL: NORIG

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究将确定胃瘫患者对去甲替林治疗的临床反应，去甲替林是一种症状调节剂/三环抗抑郁药。去甲替林是FDA批准用于治疗抑郁症的药物。这项研究将评估患者的症状和潜在的病理生理异常是否对针对内脏过敏/中央处理的去甲替林有反应。虽然这种治疗剂在许多临床实践中被用于治疗胃瘫，但缺乏证据表明这种治疗方法可能对症状性胃瘫有效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will determine the clinical responses of patients with gastroparesis to treatment with nortriptyline, a symptom modulator/tricyclic antidepressant. Nortriptyline is FDA approved for treatment of depression. This study will evaluate whether patients= symptoms and underlying pathophysiologic abnormalities respond to nortriptyline directed towards visceral hypersensitivity/central processing. Although this therapeutic agent is employed in many clinical practices for gastroparesis, there is a lack of evidence that this treatment may be effective in symptomatic gastroparesis.